Study guide
11.3 Theft, Significant Loss & Disposal of Controlled Substances
Utah MPJE Pharmacy Jurisprudence Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Utah Pharmacy Regulatory Framework, Facility Licensing & the PIC
1.1 DOPL, the Utah State Board of Pharmacy & the Sources of Utah Pharmacy Law 1.2 Federal vs. Utah Law: Following the Stricter Standard 1.3 Utah Pharmacy License Classes (A–E) & Facility Licensing 1.4 The Pharmacist-in-Charge (PIC): Duties, Self-Audits & Notifications 1.5 Facility Inspections, Ownership & Location Changes, Closing & Facility Discipline
2 Chapter 2: Pharmacist, Intern & Technician Licensure and Personnel
2.1 Pharmacist Licensure, the NAPLEX & Utah MPJE, and Licensure by Endorsement 2.2 License Renewal, Continuing Education & Reinstatement 2.3 Pharmacy Interns & Preceptors 2.4 Pharmacy Technicians, Technician Trainees & Supportive Personnel
3 Chapter 3: Unlawful & Unprofessional Conduct, Discipline, and Impairment
3.1 Unlawful Conduct, Criminal Penalties, Fines & the Disciplinary Process 3.2 Unprofessional Conduct, the APhA Code of Ethics & Utah's Conscience Law 3.3 Impairment, the Utah Professionals Health Program & Reinstatement
4 Chapter 4: Prescription Issuance, Prescriber Authority & Electronic Prescribing
4.1 Prescriber Scope of Authority in Utah 4.2 Required Prescription Elements, Oral & Faxed Orders, and Alterations 4.3 Mandatory Electronic Prescribing of Controlled Substances (EPCS) in Utah 4.4 Legitimate Medical Purpose, Corresponding Responsibility & Red Flags
5 Chapter 5: Patient Counseling, Prospective DUR, Confidentiality & Records
5.1 Patient Counseling: The Offer, Who May Counsel & Delivered Prescriptions 5.2 Prospective Drug Utilization Review & Patient Medication Profiles 5.3 Confidentiality, HIPAA & Protected Health Information 5.4 Pharmacy Records, Retention Periods & Facility Operating Standards
6 Chapter 6: Expanded Practice: Collaboration, Pharmacist Prescribing & Drug Administration
6.1 Collaborative Pharmacy Practice, Drug Therapy Management & Administration of Drugs 6.2 Self-Administered Hormonal Contraception: Standing Order & Pharmacist Prescribing 6.3 Pharmacist Prescribing Under Utah Code § 58-17b-627: Tobacco Cessation, HIV PrEP/PEP, Fluoride & Epinephrine 6.4 Vaccine Administration: DOPL's Protocol, Delegation, Emergencies & USIIS Reporting
7 Chapter 7: Opioid Overdose Prevention, Emergency Refills & Returned or Donated Drugs
7.1 Naloxone & Opioid-Safety Laws in Utah 7.2 Emergency Refills, Combined Refills & Insulin Continuity 7.3 Returned Drugs, Consumer Disposal & the Charitable Prescription Drug Recycling Program
8 Chapter 8: Controlled Substance Schedules, Registration & Security in Utah
8.1 Controlled Substance Schedules: Federal CSA & Utah-Specific Scheduling 8.2 DEA Registration & Facility Licensing 8.3 Controlled Substance Storage & Physical Security
9 Chapter 9: Dispensing Controlled Substances & the Utah Controlled Substance Database
9.1 Schedule II Prescriptions: 30-Day Window, One-Month Supply, Multiple Prescriptions & the 7-Day Acute Limit 9.2 Schedule II Partial Fills, Emergency Oral Orders & Methadone Emergency Orders 9.3 Schedule III–V Prescriptions: Refill Limits, the 80% Rule & Controlled Substance Transfers 9.4 The Utah Controlled Substance Database (CSD)
10 Chapter 10: Dispensing Standards: Labeling, Substitution, Refills, Packaging, Product Integrity & OTC Products
10.1 Prescription Labels: Utah Minimum Elements, Controlled Substance & Opioid Warnings, and Special Labels 10.2 Drug Product Selection: Generic Equivalents, Therapeutically Similar Drugs & Interchangeable Biologics 10.3 Legend-Drug Prescription Validity, Refills & Transfers 10.4 Poison Prevention Packaging Act (PPPA) & Special Packaging 10.5 Drug Product Conditions That Prohibit Dispensing: Adulterated, Misbranded, Outdated, Recalled & Suspect Products 10.6 Nonprescription Products: OTC Labeling & Packaging, Pseudoephedrine, Iodine, Schedule V & Other Restricted OTC Sales
11 Chapter 11: Acquisition, Inventory, Loss, Distribution & Delivery
11.1 Ordering Schedule II Substances: DEA Form 222 & CSOS 11.2 Controlled Substance Inventories & Utah's Schedule II Perpetual Inventory 11.3 Theft, Significant Loss & Disposal of Controlled Substances 11.4 Drug Acquisition & Distribution, Office-Use Sales, and Delivering Prescriptions to Patients
12 Chapter 12: Compounding Standards, USP Chapters & Hazardous Drugs
12.1 Non-Sterile Compounding & USP <795> Standards 12.2 Sterile Compounding & USP <797> Standards 12.3 Hazardous Drug Handling & USP <800> Standards
13 Chapter 13: Institutional, Central Processing, Remote Dispensing, Specialty Outlets & Automation
13.1 Institutional Practice: Hospitals, Pharmaceutical Administration Facilities & Emergency Drug Kits 13.2 Centralized Prescription Processing, Telepharmacy & Remote Dispensing Pharmacies 13.3 Nuclear Pharmacies, Class E Outlets & Dispensing Medical Practitioners 13.4 Automated Pharmacy Systems, Quality Assurance & Pharmacy Audits
11.3 Theft, Significant Loss & Disposal of Controlled Substances
Key Takeaways Explain This Topic AI
Under 21 CFR § 1301.76(b), a registrant must notify the local DEA Diversion Field Office in writing within ONE (1) BUSINESS DAY of discovery of any theft or significant loss of controlled substances.
The registrant must submit DEA Form 106 (Report of Theft or Loss of Controlled Substances) electronically via the DEA secure portal within 45 calendar days of discovery; paper submissions are obsolete.
Accidental breakage, spillage, or wastage of controlled substances does NOT constitute a theft or loss; it must NOT be reported on DEA Form 106, but must be documented on DEA Form 41, witnessed by two employees, and logged in perpetual records.
In-transit losses are the legal reporting responsibility of the supplier until the purchaser signs for and accepts delivery; once custody is signed for, any loss becomes the purchaser's responsibility.
Surrendering controlled substances for disposal requires transfer to a DEA-registered reverse distributor; for Schedule II substances, the reverse distributor acts as the purchaser and issues a DEA Form 222 to the pharmacy.
Last updated: September 2026
11.3 Theft, Significant Loss & Disposal of Controlled Substances
The loss, diversion, or destruction of controlled substances represents an area of intense regulatory oversight. Under federal law (21 CFR § 1301.76(b) and 21 CFR Part 1317) and Utah pharmacy regulations (Utah Admin. Code R156-17b and R156-37), registrants must comply with precise administrative procedures when controlled substances are stolen, significantly lost, or earmarked for destruction. Pharmacists must distinguish between criminal theft, unexplained significant losses, transit discrepancies, and routine accidental breakage, ensuring that reports are delivered to the proper authorities within strict statutory deadlines.
Candidates preparing for the Utah MPJE must master the timelines for DEA and DOPL notifications, the execution of DEA Form 106 and DEA Form 41, and the lawful mechanisms for reverse distribution under the Secure and Responsible Drug Disposal Act.
Theft or Significant Loss Reporting: The Two-Step DEA Framework
When a registrant discovers a theft or significant loss of controlled substances, federal law (21 CFR § 1301.76(b)) establishes a mandatory two-step reporting protocol:
Loading diagram...
Step 1: Initial Written Notification (Within 1 Business Day)
Under 21 CFR § 1301.76(b), the registrant must notify the local DEA Diversion Field Office (Utah is served by DEA's Rocky Mountain Field Division and its Salt Lake City office) in writing within ONE (1) BUSINESS DAY of discovery of any theft or significant loss:
The initial notification may be submitted via letter, fax, or secure email transmission to the field office.
The notification serves as an immediate regulatory alert, establishing that an investigation has commenced.
The registrant does not need to know the final quantity or all contributing factors at this initial stage.
Step 2: Electronic DEA Form 106 (Within 45 Calendar Days)
Following the initial 1-business-day notification, the registrant must conduct a thorough internal investigation to reconcile physical counts, audit perpetual logs, and determine the exact extent of the loss:
Electronic Filing : The registrant must file a complete and accurate DEA Form 106 ( Report of Theft or Loss of Controlled Substances ) through DEA's Diversion Control Division secure network application (21 CFR § 1301.76(b)).
45-Day Deadline : Under a DEA rule published in June 2023, DEA Form 106 is due within 45 days after discovery of the theft or loss (21 CFR § 1301.76(b)). The parallel rule for non-practitioners such as distributors says 45 calendar days (21 CFR § 1301.74(c)).
Investigation Yielding No Loss : If the pharmacy's investigation reveals that no actual theft or significant loss occurred (e.g., an inventory discrepancy was resolved as an initial miscount or bookkeeping data entry error), no DEA Form 106 needs to be filed. DEA's Pharmacist's Manual strongly recommends notifying DEA in writing to resolve the initial report and explain why no Form 106 was filed. Clerical miscounts and inventory adjustments are not reported on Form 106.
Important
Before the 2023 rule, the regulation required a DEA Form 106 but set no deadline for it. Today, 21 CFR § 1301.76(b) requires filing it through DEA's secure network application within 45 days after discovery . The written notice to the DEA field office is still due within one business day .
Evaluating "Significant Loss"
Neither the federal Controlled Substances Act nor DEA's rules sets a numerical threshold for a "significant loss"; the registrant must use its judgment. Under 21 CFR § 1301.76(b), a registrant should consider, among others, these six factors:
Actual Quantity Lost in Relation to Business Type : A loss of 50 tablets of oxycodone is extraordinarily significant for a small retail pharmacy, whereas 50 tablets lost in a multi-million-unit wholesale distribution center might be evaluated differently.
Specific Controlled Substances Lost : The loss of high-potency Schedule II opioids (fentanyl, hydromorphone, oxycodone) or Schedule II stimulants (amphetamine, methylphenidate) carries substantially higher diversion significance than an equivalent quantity of Schedule V cough syrups.
Association with Specific Individuals : Whether the loss can be tied to specific pharmacy personnel, contract cleaners, temporary relief staff, or unique suspicious dispensing patterns.
Pattern of Repeated Losses : Multiple small, unexplained shortages occurring over weeks or months (e.g., 5 tablets missing every Friday) constitute a significant loss pattern indicating ongoing pilferage, even if each individual loss appears minor.
Diversion Likelihood : Whether the missing substances are popular street drugs subject to black market demand.
Local and Regional Trends : Whether the drug is currently targeted in burglaries, robberies, or illicit street sales within the local Utah community.
Note
The DEA's official administrative stance is unambiguous: when in doubt regarding whether an unexplained shortage is "significant," the registrant should err on the side of caution and submit a formal report.
In-Transit Losses: Supplier vs. Purchaser Responsibility
When controlled substances are stolen or lost while being shipped from a manufacturer or wholesale distributor to a purchasing pharmacy, reporting responsibility is determined by the transfer of legal custody :
Supplier Responsibility : Under 21 CFR § 1301.74(c), the supplier (distributor) is responsible for reporting in-transit thefts and losses by its agent or its common or contract carrier within 1 business day and filing DEA Form 106. DEA's Pharmacist's Manual applies this to any loss from a shipment the purchaser has not signed for or taken custody of.
Purchaser Responsibility : The moment the pharmacist or authorized pharmacy agent inspects the shipping manifest, signs the courier delivery receipt, and accepts custody of the containers, transit is legally complete. If the purchaser subsequently discovers a loss after signing the receipt, the purchaser must report the loss to the DEA on Form 106.
Central Fill Operations : When a central fill pharmacy contracts with a carrier to transport filled prescriptions to a retail pharmacy, the central fill pharmacy reports in-transit losses on DEA Form 106. When the retail pharmacy contracts with the carrier to retrieve them, the retail pharmacy reports (21 CFR § 1301.76(d)).
Utah State Notifications: DOPL & Law Enforcement
Utah's controlled substance rule adds state notice duties to the federal ones. Under R156-37-602(2) , a licensee who has any theft (including diversion) or significant loss of controlled substances must immediately :
file the appropriate forms with DEA, with a copy to DOPL , directed to the Investigation Bureau; and
report the incident to the local law enforcement agency .
Related Utah requirements:
Accountability. Failing to keep controls a prudent licensee would keep against diversion, theft, or shortage, or failing to account for shortages , is unprofessional conduct (R156-37-502(4)–(5)). The PIC must maintain effective controls against theft and diversion (R156-17b-603(3)(k)).
Wholesalers. Class C wholesalers must report significant inventory discrepancies involving counterfeit or contraband drugs, and suspected criminal activity involving drug inventory, to DOPL (and to FDA and DEA as applicable) within three business days (R156-17b-615(15)(f)–(g)).
Records. Keep controlled substance records, including theft and loss reports, five years (R156-37-602(3)), and keep hard copies of surrender and destruction reports (R156-17b-614a(14)). Disposal follows 21 CFR Part 1317 , and disposal records are also kept five years (R156-37-606).
Controlled Substance Disposal & Destruction (21 CFR Part 1317)
Under the Secure and Responsible Drug Disposal Act of 2010 and 21 CFR Part 1317, controlled substances must be rendered non-retrievable to prevent diversion. Pharmacies possess two primary avenues for handling unwanted or unusable stock:
1. Reverse Distribution (The Primary Commercial Method)
A community or institutional pharmacy does not directly destroy controlled substances on site. Instead, unwanted, expired, adulterated, or recalled stocks are transferred to a DEA-registered reverse distributor :
Schedule II Transfer : The reverse distributor acts as the purchaser and must issue a single-sheet DEA Form 222 (or CSOS equivalent) to the pharmacy. The pharmacy acts as the supplier and fulfills the order by shipping the Schedule II stock to the reverse distributor.
Schedule III–V Transfer : Documented on an official commercial invoice detailing drug name, strength, dosage form, quantity, date, and registered names/addresses of both parties.
Destruction Execution : The reverse distributor destroys the substances to a non-retrievable state and is responsible for the DEA Form 41 ( Registrant Record of Controlled Substances Destroyed ). The pharmacy does not use Form 41 to record the transfer; its Form 222 copy or distribution record is its record.
2. Accidental Breakage and Spillage (The DEA Form 41 Rule)
A critical distinction frequently tested on the MPJE is the difference between a loss and accidental breakage/spillage:
Not a Theft or Loss : If a technician drops a 500 mL stock bottle of liquid oral morphine concentrate or knocks over an open container of oxycodone tablets onto a wet compounding floor, rendering the drug unsalvageable, this is legally classified as breakage or spillage , NOT a theft or loss.
No DEA Form 106 : Witnessed breakage or spillage does not require notification to DEA, and DEA says Form 106 should be used only for thefts and significant losses.
Recoverable drug : If the drug is still recoverable, dispose of it like any other inventory (on-site destruction, a reverse distributor, or DEA assistance under 21 CFR § 1317.05).
Non-recoverable drug on DEA Form 41 : DEA's position is that non-recoverable breakage or spillage must be recorded on DEA Form 41 , signed by two individuals who can testify that the breakage or spillage occurred , and kept in the pharmacy's files. Utah also requires a perpetual inventory of Schedule II drugs (R156-17b-605(6)), so the pharmacy reconciles the book balance.
Event / Scenario Legal Classification Governing Form Reporting Timeline Required Notification Agencies
Burglary / Night Break-In Theft / Criminal Diversion DEA Form 106 (Electronic) Initial notice: 1 Business Day ; Form 106: 45 Calendar Days DEA Field Office, DOPL, Local Police
Unexplained Inventory Loss Significant Loss DEA Form 106 (Electronic) Initial notice: 1 Business Day ; Form 106: 45 Days DEA Field Office, DOPL, Local Police
In-Transit Shortage (Unsigned) Supplier Transit Loss DEA Form 106 Supplier files within statutory deadlines DEA Field Office (Supplier duty)
Liquid Bottle Drop / Spill Accidental Breakage / Waste DEA Form 41 (kept on file) Maintained in pharmacy records Signed by 2 witnesses; reconcile C-II perpetual inventory
Expired Stock Disposal Reverse Distribution Transfer DEA Form 222 (C-II) / Invoice (C-III–V) Executed prior to commercial shipment Reverse distributor submits Form 41 to DEA
Common MPJE Traps & Scenario Analysis
Spilled Narcotic Reporting Trap : An MPJE question describes a pharmacist dropping a glass bottle of liquid methadone that shatters and seeps into a sink drain. The question asks which form must be filed with the DEA within one business day. No Form 106 is filed. Non-recoverable spillage is recorded on DEA Form 41, signed by two witnesses, kept on file, and reconciled in the Schedule II perpetual inventory.
The 45-Day vs. 1-Day Distinction : Candidates often confuse the initial 1-business-day written notice with the final DEA Form 106. The initial notice is due within 1 business day ; the detailed electronic Form 106 is due within 45 calendar days .
Reverse Distributor Form 222 Execution : When sending expired OxyContin to a reverse distributor, candidates mistakenly think the pharmacy issues a Form 222. In reverse distribution, the reverse distributor is the purchaser and issues the Form 222 to the pharmacy.
In-Transit Signing Trap : If a pharmacist signs the delivery driver's electronic clipboard before opening the tote, and then opens the tote to find three bottles of hydrocodone missing, the pharmacy must report the loss on Form 106 because custody was legally accepted upon signature.